190 related articles for article (PubMed ID: 18974298)
1. Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression.
Roodink I; Kats G; van Kempen L; Grunberg M; Maass C; Verrijp K; Raats J; Leenders W
Am J Pathol; 2008 Dec; 173(6):1873-81. PubMed ID: 18974298
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of semaphorin 3E is involved in the gastric cancer development.
Maejima R; Tamai K; Shiroki T; Yokoyama M; Shibuya R; Nakamura M; Yamaguchi K; Abue M; Oikawa T; Noguchi T; Miura K; Fujiya T; Sato I; Iijima K; Shimosegawa T; Tanaka N; Satoh K
Int J Oncol; 2016 Sep; 49(3):887-94. PubMed ID: 27572291
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of semaphorin as a novel strategy for therapeutic angiogenesis.
Moriya J; Minamino T; Tateno K; Okada S; Uemura A; Shimizu I; Yokoyama M; Nojima A; Okada M; Koga H; Komuro I
Circ Res; 2010 Feb; 106(2):391-8. PubMed ID: 19940264
[TBL] [Abstract][Full Text] [Related]
4. Vascular Sema3E-Plexin-D1 Signaling Reactivation Promotes Post-stroke Recovery through VEGF Downregulation in Mice.
Yu R; Kim NS; Li Y; Jeong JY; Park SJ; Zhou B; Oh WJ
Transl Stroke Res; 2022 Feb; 13(1):142-159. PubMed ID: 33978913
[TBL] [Abstract][Full Text] [Related]
5. Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis.
Mazzotta C; Romano E; Bruni C; Manetti M; Lepri G; Bellando-Randone S; Blagojevic J; Ibba-Manneschi L; Matucci-Cerinic M; Guiducci S
Arthritis Res Ther; 2015 Aug; 17(1):221. PubMed ID: 26292963
[TBL] [Abstract][Full Text] [Related]
6. Semaphorin 3d and semaphorin 3e direct endothelial motility through distinct molecular signaling pathways.
Aghajanian H; Choi C; Ho VC; Gupta M; Singh MK; Epstein JA
J Biol Chem; 2014 Jun; 289(26):17971-9. PubMed ID: 24825896
[TBL] [Abstract][Full Text] [Related]
7. Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism.
Kim J; Oh WJ; Gaiano N; Yoshida Y; Gu C
Genes Dev; 2011 Jul; 25(13):1399-411. PubMed ID: 21724832
[TBL] [Abstract][Full Text] [Related]
8. Binding and complementary expression patterns of semaphorin 3E and plexin D1 in the mature neocortices of mice and monkeys.
Watakabe A; Ohsawa S; Hashikawa T; Yamamori T
J Comp Neurol; 2006 Nov; 499(2):258-73. PubMed ID: 16977617
[TBL] [Abstract][Full Text] [Related]
9. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
10. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice.
Casazza A; Finisguerra V; Capparuccia L; Camperi A; Swiercz JM; Rizzolio S; Rolny C; Christensen C; Bertotti A; Sarotto I; Risio M; Trusolino L; Weitz J; Schneider M; Mazzone M; Comoglio PM; Tamagnone L
J Clin Invest; 2010 Aug; 120(8):2684-98. PubMed ID: 20664171
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol-4-phosphate 5-kinase and GEP100/Brag2 protein mediate antiangiogenic signaling by semaphorin 3E-plexin-D1 through Arf6 protein.
Sakurai A; Jian X; Lee CJ; Manavski Y; Chavakis E; Donaldson J; Randazzo PA; Gutkind JS
J Biol Chem; 2011 Sep; 286(39):34335-45. PubMed ID: 21795701
[TBL] [Abstract][Full Text] [Related]
12. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.
Casazza A; Kigel B; Maione F; Capparuccia L; Kessler O; Giraudo E; Mazzone M; Neufeld G; Tamagnone L
EMBO Mol Med; 2012 Mar; 4(3):234-50. PubMed ID: 22247010
[TBL] [Abstract][Full Text] [Related]
13. Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy?
Roodink I; Raats J; van der Zwaag B; Verrijp K; Kusters B; van Bokhoven H; Linkels M; de Waal RM; Leenders WP
Cancer Res; 2005 Sep; 65(18):8317-23. PubMed ID: 16166308
[TBL] [Abstract][Full Text] [Related]
14. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis.
Christensen C; Ambartsumian N; Gilestro G; Thomsen B; Comoglio P; Tamagnone L; Guldberg P; Lukanidin E
Cancer Res; 2005 Jul; 65(14):6167-77. PubMed ID: 16024618
[TBL] [Abstract][Full Text] [Related]
16. Dysfunctional SEMA3E signaling underlies gonadotropin-releasing hormone neuron deficiency in Kallmann syndrome.
Cariboni A; André V; Chauvet S; Cassatella D; Davidson K; Caramello A; Fantin A; Bouloux P; Mann F; Ruhrberg C
J Clin Invest; 2015 Jun; 125(6):2413-28. PubMed ID: 25985275
[TBL] [Abstract][Full Text] [Related]
17. Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers.
Luchino J; Hocine M; Amoureux MC; Gibert B; Bernet A; Royet A; Treilleux I; Lécine P; Borg JP; Mehlen P; Chauvet S; Mann F
Cancer Cell; 2013 Nov; 24(5):673-85. PubMed ID: 24139859
[TBL] [Abstract][Full Text] [Related]
18. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.
Kigel B; Varshavsky A; Kessler O; Neufeld G
PLoS One; 2008 Sep; 3(9):e3287. PubMed ID: 18818766
[TBL] [Abstract][Full Text] [Related]
19. Semaphorin 3E-Plexin-D1 signaling controls pathway-specific synapse formation in the striatum.
Ding JB; Oh WJ; Sabatini BL; Gu C
Nat Neurosci; 2011 Dec; 15(2):215-23. PubMed ID: 22179111
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
